Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2020

01-12-2020 | Fifth Disease | Research Letter

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome

Authors: Etienne Dufranc, Arnaud Del Bello, Julie Belliere, Nassim Kamar, Stanislas Faguer, on behalf of the TAIDI (Toulouse Acquired Immune Deficiency and Infection) study group

Published in: Critical Care | Issue 1/2020

Login to get access

Excerpt

To the Editor, …
Literature
1.
La Rosée P, Horne AC, Hines M, Greenwood TVB, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood Ame Soc Hematol. 2019;133:2465–77.
2.
Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613–20.CrossRef
3.
Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124–5.CrossRef
4.
Faguer S, Vergez F, Peres M, Ferrandiz I, Casemayou A, Belliere J, et al. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis. Hematol Oncol. 2016;34(1):55–7.
5.
Ahmed A, Merrill SA, Alsawah F, Bockenstedt P, Campagnaro E, Devata S, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6:e630–7.CrossRef
Metadata
Title
IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
Authors
Etienne Dufranc
Arnaud Del Bello
Julie Belliere
Nassim Kamar
Stanislas Faguer
on behalf of the TAIDI (Toulouse Acquired Immune Deficiency and Infection) study group
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-02878-7

Other articles of this Issue 1/2020

Critical Care 1/2020 Go to the issue

Research Letter

Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times?

Editorial

COVID-19 and ethics in the ICU

Research

Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study

Letter

The importance of a “socially responsible” approach during COVID-19: the invisible heroes of science in Italy

Commentary

Acute kidney injury in SARS-CoV-2 infected patients

Research

Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial